Barlow Wealth Partners Inc. Makes New $222,000 Investment in Pfizer Inc. (NYSE:PFE)

Barlow Wealth Partners Inc. bought a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,715 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Trifecta Capital Advisors LLC raised its holdings in shares of Pfizer by 3.7% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 325 shares in the last quarter. Confluence Wealth Services Inc. lifted its position in Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares during the last quarter. Carr Financial Group Corp grew its stake in shares of Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 355 shares in the last quarter. Lafayette Investments Inc. increased its holdings in shares of Pfizer by 2.2% in the 3rd quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 368 shares during the last quarter. Finally, Safeguard Investment Advisory Group LLC lifted its holdings in shares of Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $36.00.

Pfizer Stock Down 1.4 %

NYSE PFE traded down $0.39 during midday trading on Tuesday, hitting $27.78. 65,400,901 shares of the company traded hands, compared to its average volume of 43,591,664. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market cap of $157.28 billion, a PE ratio of -462.84, a price-to-earnings-growth ratio of 1.17 and a beta of 0.63. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company’s 50-day simple moving average is $26.92 and its 200-day simple moving average is $28.12.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the firm posted $1.23 earnings per share. The company’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.05%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.